Price
CHART BY
Frequently asked questions
What is Affimed's market capitalization?
The market capitalization of Affimed is $87.67K. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Affimed?
Affimed's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -5.693. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Affimed's stock?
Currently, 1 analysts cover Affimed's stock, with a consensus target price of $0.404. Analyst ratings provide insights into the stock's expected performance.
What is Affimed's revenue over the trailing twelve months?
Over the trailing twelve months, Affimed reported a revenue of $1.09M.
What is the EBITDA for Affimed?
Affimed's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$88.02M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Affimed?
Affimed has a free cash flow of -$96.01M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Affimed have, and what sector and industry does it belong to?
Affimed employs approximately 78 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Affimed's shares?
The free float of Affimed is 13.50M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $87.67K
- EPS (TTM)
- -5.693
- Free Float
- 13.50M
- Revenue (TTM)
- $1.09M
- EBITDA (TTM)
- -$88.02M
- Free Cashflow (TTM)
- -$96.01M
Analyst Ratings
The price target is $0.404 and the stock is covered by 1 analysts.
Buy
0
Hold
1
Sell
0
Information
Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.
- Employees
- 78
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- NL0015001ZQ0
- Primary Ticker
- AFMD
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet